Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 368,832,320
  • Shares Outstanding, K 2,686,520
  • Annual Sales, $ 71,890 M
  • Annual Income, $ 16,540 M
  • 36-Month Beta 0.82
  • Price/Sales 5.17
  • Price/Cash Flow 16.71
  • Price/Book 5.02

Price Performance

See More
Period Period Low Period High Performance
1-Month
136.60 +1.03%
on 11/22/17
143.75 -3.99%
on 10/26/17
-3.63 (-2.56%)
since 10/24/17
3-Month
129.05 +6.94%
on 09/29/17
144.35 -4.39%
on 10/23/17
+5.12 (+3.85%)
since 08/24/17
52-Week
109.32 +26.24%
on 12/07/16
144.35 -4.39%
on 10/23/17
+24.94 (+22.06%)
since 11/23/16

Most Recent Stories

More News
J&J & Glaxo's Jucala Approval Puts Spotlight on HIV Space

As HIV and AIDS have limited medical cure but huge medical need, we see how different companies are trying to tap into this huge market.

MYL : 37.37 (+0.24%)
JNJ : 138.01 (+0.52%)
MRK : 54.35 (-0.04%)
ABBV : 94.72 (+0.26%)
GILD : 72.46 (-0.49%)
GSK : 35.04 (-0.06%)
Cancer Space Update: 2 Drugs Receive Regulatory Nod in EU

This week the European Commission granted approval to Zejula for ovarian cancer and for label expansion of Tasigna in first-line Ph+ chronic myeloid leukemia.

CLDX : 2.90 (+0.35%)
AZN : 33.84 (+0.03%)
JNJ : 138.01 (+0.52%)
MRK : 54.35 (-0.04%)
LLY : 84.03 (+0.42%)
NVS : 85.08 (+0.71%)
RHHBY : 31.6000 (-0.19%)
Here's Why Merck Stock Is Down in 2017 Despite a Rising Industry

Shares of Merck (MRK) have declined so far this year compared to an increase witnessed by the industry due to some notable pipeline setbacks.

AZN : 33.84 (+0.03%)
JNJ : 138.01 (+0.52%)
MRK : 54.35 (-0.04%)
LLY : 84.03 (+0.42%)
Pharma Stock Roundup: FDA Approves J&J, Glaxo HIV Drug, Roche Presents Data

Key highlights this week include the FDA approval of GlaxoSmithKline (GSK) and J&J's new HIV drug and study data from Roche.

AZN : 33.84 (+0.03%)
JNJ : 138.01 (+0.52%)
MRK : 54.35 (-0.04%)
NVS : 85.08 (+0.71%)
RHHBY : 31.6000 (-0.19%)
GSK : 35.04 (-0.06%)
BMY : 61.43 (+0.47%)
Dow 30 Stock Roundup: Boeing Secures $11B Order, Apple Buys Vrvana

The Dow experienced a relatively sluggish holiday shortened week, suffering losses during two trading sessions.

GOOGL : 1,056.52 (+0.44%)
AAPL : 174.97 (+0.01%)
CSCO : 36.49 (+0.11%)
VZ : 47.01 (-0.19%)
JPM : 98.32 (-0.32%)
JNJ : 138.01 (+0.52%)
GS : 235.95 (-0.20%)
AXP : 93.48 (-0.36%)
FB : 182.78 (+1.06%)
GSK : 35.04 (-0.06%)
GE : 18.19 (+0.22%)
BA : 265.88 (+0.28%)
WMT : 96.62 (+0.22%)
Psoriatic Arthritis - Pipeline Review, H2 2017 - Research and Markets

The "Psoriatic Arthritis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering. Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis...

NVO : 52.24 (+0.77%)
JNJ : 138.01 (+0.52%)
AGN : 173.53 (-0.74%)
ABBV : 94.72 (+0.26%)
AMGN : 170.12 (+0.09%)
PFE : 35.49 (+0.17%)
FSNUF : 78.7560 (-1.37%)
LLY : 84.03 (+0.42%)
RIGL : 4.25 (unch)
NHKFF : 14.4000 (unch)
ACRS : 23.27 (+0.65%)
GLPG : 92.23 (+0.30%)
UCBJF : 72.7800 (+3.25%)
Will a 'Huge Tax Cut' Ease Burden for MedTech Players?

How is the MedTech industry placed in the wake of the current political conundrum surrounding tax reforms?

SNN : 35.78 (-0.03%)
ABMD : 199.74 (+0.44%)
JNJ : 138.01 (+0.52%)
MDT : 83.25 (+1.11%)
JP Morgan Launches US Dividend ETF

JP Morgan rolls out multi-cap US Dividend ETF.

HFC : 44.05 (-0.77%)
JDIV : 25.33 (+0.89%)
DVY : 95.57 (-0.04%)
JNJ : 138.01 (+0.52%)
SDY : 93.54 (-0.05%)
DLR : 117.54 (+0.28%)
MCD : 169.11 (+0.04%)
NNN : 42.68 (+0.31%)
MSFT : 83.26 (+0.18%)
LMT : 315.82 (+0.30%)
T : 34.81 (-0.17%)
VIG : 98.25 (+0.12%)
PEP : 115.90 (+0.71%)
CME : 141.86 (-0.01%)
SKT : 24.40 (unch)
DWDP : 71.16 (+0.79%)
J&J Seeks Darzalex's Label Expansion in First-Line Setting

Johnson & Johnson (JNJ) has submitted regulatory applications in the United States and EU for label expansion of Darzalex as first-line therapy for multiple myeloma.

CELG : 104.50 (-0.63%)
JNJ : 138.01 (+0.52%)
AMGN : 170.12 (+0.09%)
BMY : 61.43 (+0.47%)
JP Morgan Launches US Dividend ETF

JP Morgan rolls out multi-cap US Dividend ETF.

HFC : 44.05 (-0.77%)
JDIV : 25.33 (+0.89%)
DVY : 95.57 (-0.04%)
JNJ : 138.01 (+0.52%)
SDY : 93.54 (-0.05%)
DLR : 117.54 (+0.28%)
MCD : 169.11 (+0.04%)
NNN : 42.68 (+0.31%)
MSFT : 83.26 (+0.18%)
LMT : 315.82 (+0.30%)
T : 34.81 (-0.17%)
VIG : 98.25 (+0.12%)
PEP : 115.90 (+0.71%)
CME : 141.86 (-0.01%)
SKT : 24.40 (unch)
DWDP : 71.16 (+0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 138.97
1st Resistance Point 138.49
Last Price 138.01
1st Support Level 137.42
2nd Support Level 136.83

See More

52-Week High 144.35
Last Price 138.01
Fibonacci 61.8% 130.97
Fibonacci 50% 126.84
Fibonacci 38.2% 122.70
52-Week Low 109.32

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart